Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EPIM-001,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EPIM-001, an anti-PD-L1 tumor-targeting IL2 agonist with reduced IL2Rα binding and enhanced IL2Rβ binding, activates CD8+ T Cells and NK cells better than WT IL2, whilst only weakly activating Tregs.
Product Name : EPIM-001
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : EPIM-001,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EPIM-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $30.0 million
Deal Type : Series A Financing
Elpis Biopharmaceuticals Debuts with Series A Funding and Establishment of Scientific Advisory Board
Details : Funds will be allocated for the company's pre-clinical pipeline development. Elpis' lead immuno-oncology product candidates EPIM-001 to treat solid tumor indications, and EPC-001 are being advanced to enter clinical studies.
Product Name : EPIM-001
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
October 29, 2020
Lead Product(s) : EPIM-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $30.0 million
Deal Type : Series A Financing
Reset All
